Results 21 to 30 of about 27,196 (258)

Bispecific antibodies and their applications [PDF]

Journal of Hematology & Oncology, 2015
Bispecific antibodies (BsAbs) recognize two different epitopes. This dual specificity opens up a wide range of applications, including redirecting T cells to tumor cells, blocking two different signaling pathways simultaneously, dual targeting of different disease mediators, and delivering payloads to targeted sites.
Fan, Gaowei, Wang, Zujian, Hao, Mingju, Li, Jinming   +3 more
openaire   +2 more sources

Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth

Journal for ImmunoTherapy of Cancer, 2020
Background Small cell lung cancer (SCLC) accounts for 15% of lung cancers, and the primary treatment of this malignancy is chemotherapy and radiotherapy.
Xin Chen, Norhan Amar, Yuankui Zhu, Chunguang Wang, Chunjiao Xia, Xiaoqing Yang, Dongde Wu, Mingqian Feng   +7 more
doaj   +1 more source

Bispecific antibody toxicities. [PDF]

CMAJ
Britto J, Mian H, Davies GA, Balitsky AK.   +3 more
europepmc   +3 more sources

The making of bispecific antibodies [PDF]

mAbs, 2017
During the past two decades we have seen a phenomenal evolution of bispecific antibodies for therapeutic applications. The 'zoo' of bispecific antibodies is populated by many different species, comprising around 100 different formats, including small molecules composed solely of the antigen-binding sites of two antibodies, molecules with an IgG ...
Brinkmann, Ulrich, Kontermann, Roland E.
openaire   +2 more sources

Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells. [PDF]

PLoS ONE, 2018
Muc1 is one of the most studied tumor antigens. However, antibodies or antibody-toxin conjugates against Muc1 have not shown significant efficacy for tumors with Muc1 overexpression.
Yumei Li, Changhua Zhou, Jing Li, Jiayu Liu, Limin Lin, Li Li, Donglin Cao, Qing Li, Zhong Wang   +8 more
doaj   +1 more source

Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency

mAbs, 2023
Antibody CAP256-VRC26.25 targets the second hypervariable region (V2) at the apex of the HIV envelope (Env) trimer with extraordinary neutralization potency, although less than optimal breadth. To improve breadth, we linked the light chain of CAP256V2LS,
Baoshan Zhang, Jason Gorman, Young D. Kwon, Amarendra Pegu, Cara W. Chao, Tracy Liu, Mangaiarkarasi Asokan, Michael F. Bender, Tatsiana Bylund, Leland Damron, Deepika Gollapudi, Paula Lei, Yile Li, Cuiping Liu, Mark K. Louder, Krisha McKee, Adam S. Olia, Reda Rawi, Arne Schön, Shuishu Wang, Eun Sung Yang, Yongping Yang, Kevin Carlton, Nicole A. Doria-Rose, Lawrence Shapiro, Michael S. Seaman, John R. Mascola, Peter D. Kwong   +27 more
doaj   +1 more source

A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies

mBio, 2020
Broadly neutralizing antibodies (bNAbs) can prevent and control an HIV-1 infection, but their breadth is invariably too limited for use as monotherapy. To address this problem, bi- and trispecific antibody-like constructs have been developed.
Meredith E. Davis-Gardner, Barnett Alfant, Jesse A. Weber, Matthew R. Gardner, Michael Farzan   +4 more
doaj   +1 more source

A new approach to produce IgG4-like bispecific antibodies

Scientific Reports, 2021
While achieving rapid developments in recent years, bispecific antibodies are still difficult to design and manufacture, due to mispair of both heavy and light chains. Here we report a novel technology to make bispecific molecules.
Caizhi Zhao, Wei Zhang, Guihua Gong, Liping Xie, Ming-Wei Wang, Youjia Hu   +5 more
doaj   +1 more source

Bispecific antibodies

Drug Discovery Today, 2015
Bispecific antibodies have emerged as molecules with a multitude of ...
Kontermann, Roland E., Brinkmann, Ulrich
openaire   +3 more sources

Effective clearance of rituximab-resistant tumor cells by breaking the mirror-symmetry of immunoglobulin G and simultaneous binding to CD55 and CD20

Scientific Reports, 2023
Complement-dependent cytotoxicity (CDC), which eliminates aberrant target cells through the assembly and complex formation of serum complement molecules, is one of the major effector functions of anticancer therapeutic antibodies.
Sang Min Lee, Sung-Won Min, Hyeong Sun Kwon, Gong-Deuk Bae, Ji Hae Jung, Hye In Park, Seung Hyeon Lee, Chung Su Lim, Byoung Joon Ko, Ji Chul Lee, Sang Taek Jung   +10 more
doaj   +1 more source